Clexio is a multi-asset, CNS-first clinical stage pharmaceutical company with a broad and growing pipeline. We are dedicated to developing novel therapies for patients suffering from neurological and psychiatric conditions.
We are developing novel therapies to address patients’ unmet needs in Major Depressive Disorder, Chronic Pruritus of neurological origin, Neuropathic Pain, Cluster Headache and Parkinson ’s disease. Our lead drug candidate is currently in a Phase 2 multicenter study in the United States.
One of our driving principles is to invent new therapeutic modalities and bring them quickly from an idea to Proof of Concept and then to full clinical development. We identify points of convergence between validated mechanisms of action and technology, to generate new patient-centric possibilities.
Our multidisciplinary team brings years of experience in the Pharmaceutical and Biotech industries and encompasses end-to-end drug development expertise, from early stage to advanced clinical stages and regulatory approvals.
Individually and as a team, we are excited every day to use our expertise to innovate, integrate, apply, and develop new and effective solutions for patients.
KEYSTONE BIO (KB) is a highly compact Biotech company focused on the newly emerging oral-systemic healthcare market(s)as they pertain to the massive inflammatory/neuro-degenerative and cardio-metabolic drug markets by advancing a truly disruptive precision bio-therapeutic for inflammation and disease(s).
More specifically the company is bringing a precision bio-therapeutic (“Prevevent”-monoclonal antibody) through a second Phase 1 clinical trial with a planned later completed Phase 2a/b trials and licensing exits.
PrecisionLife is a global techbio company driving precision medicine in chronic diseases with combinatorial analytics and patient stratification that is powering more personalized drug discovery, clinical development, and healthcare.
STALICLA is a Swiss clinical stage biotech company deploying and applying a first in class discovery platform to bring precision medicine to patients with Neurodevelopmental Disorders (NDDs), with a first application in Autism Spectrum Disorder (ASD).
STALICLA has assembled a world-class team of 26 seasoned drug developers, clinicians, data scientists and computational biologists.
DEPI, the company's NDD precision medicine platform leveraging on ML and transcriptomics technology, has reached proof of concept for its capacity to characterize biologically similar subgroups of patients within highly variable populations of patients with neurodevelopmental disorders, and to further identify tailored treatment candidates.
To further advance its drug discovery platform and pipeline, STALICLA has established strong networks within top tier research and clinical centers in the United States and Europe.
STALICLA currently has one precision medicine candidate in the clinic and plans to bring two assets into Phase 2 in 2022.
The company is also advancing collaborative alliances with strategic third party pipelines.
STALICLA has raised USD 27M to date and is rapidly scaling its platform and clinical development activity. For more information, please visit company's website.
Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of immunology, infectious disease, and central nervous system (CNS) product candidates. Tonix is publicly traded on Nasdaq: TNXP.
Zeto, Inc. is an award-winning privately held medical technology company located in Santa Clara, CA focused on transforming the way electroencephalography (EEG) is performed at hospitals and clinics. Zeto's revolutionary FDA-cleared EEG headset and cloud platform bring the traditional EEG procedure to the 21st century. The company plans to leverage its hardware and software technology to improve noninvasive monitoring of the brain's electrical activity and achieve better outcomes for neurological conditions such as epilepsy, sleep disorders, autism, stroke and concussion.
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA
AMO Pharma is a CNS Orphan Drug company with multiple clinical stage programs and a lead compound expecting to file its NDA next year.
US/UK based AMO has deep expertise in rare genetic diseases in the neurodevelopmental space and has multiple clinical stage programs showing positive data including a GSK3β inhibitor in Phase III for Congenital Myotonic dystrophy and a Ras Inhibitor in Phase II for Phelan McDermid syndrome, Neurofibromatosis type 1 and Noonan Syndrome.
The inception of ANEUROTECH is the result of Dr. Erik Buntinx, Founding CEO & Inventor, +3 decades of experience in the clinical development of neuroscience blockbusters in collaboration with Big Pharma such as risperidone.
ANEUROTECH is developing its late stage Phase IIIB drug ANT01 in Partial Responsive Depression (PRD). ANT01 is an once daily, orally-administered small molecule to Potentiate Initial Antidepressant Therapies.
Additionally, ANT01 is oriented to attack Subjective Cognitive Decline, a clinical syndrome that very offently is associated with PRD and for which currently no treatment exists.
This established drug ANT01 acts uniquely as a combined High Selective Serotonin 2A / Dopamine 4 receptor (5-HT2A/D4DR) Blocker in the brain.
In the US, there are only 3 drugs approved for the adjunctive treatment of Partial Depressive Disorder (PRD). Unfortunately, all these come with a significant side‑effect burden such as the risk of motor side effects and the metabolic syndrome, responsible for a significant problem of non-adherence and moreover non durability of treatment.
As such, having an annual incidence of around 1.8%, PRD represents a significant unmet medical need.
Taken in to account that only in the US around 3 M patients per year are diagnosed with PRD after an initial treatment with an antidepressant, a superior add-on treatment option as with ANT01, represents a major market opportunity. As a base case, ANT01 could hit an annual sales of over $1.5b. However, with a mean 9/12 month treatment we assume treatment in 15/20% of newly diagnosed target patients and an annual peak sales of USD 3.3 to 6.0 billion respectively.
Since ANT01 recently has been endorsed by the FDA for its Pivotal Development Program, launch is planned in 2018.
ANEUROTECH is looking for investors to bring ANT01 up to PhIIIB Top Line Results followed by an acquisition by a commercial partner.
Bioasis Technologies, Inc. [TSXV: BTI.V] / [OTCMKTS: BIOAF]
Bioasis Technologies Inc. is a biopharmaceutical company developing the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier ("BBB") and the treatment of CNS disorders in areas of high unmet medical need, including rare genetic disease, brain cancers and neurodegenerative diseases and pain.
Cerecin is a biopharmaceutical company focused on developing drugs to treat and prevent diseases of the brain. Cerecin is one of the leading companies focused on the area of neurometabolism. The company’s development program leverages its extensive experience in lipid science to explore the potential therapeutic benefits of ketogenic drugs. Cerecin has a highly experienced management team based out of its dual headquarters in US and Singapore.
Herantis focuses on disease modifying, CDNF-based therapies for Parkinson’s disease that aim to restore proteostasis, body’s natural neuronal protective mechanism. A failure in proteostasis results in pathological accumulation of protein aggregates, neuroinflammation and various forms of cellular stress that is widely implicated in the development of neurodegenerative diseases such as Parkinson’s and Alzheimer’s disease. CDNF is a protein that occurs naturally in the body. Its role is to protect neurons by balancing proteostasis, thereby preventing and counteracting disease generating mechanisms.
Herantis molecules in development are CDNF-based; HER-096 (a synthetic peptide) and rhCDNF (a biological protein). HER-096 and rhCDNF have both demonstrated to have a multimodal mechanism of action mimicking CDNF and to improve functional recovery of damaged neurons in preclinical models. Importantly, HER-096 has been shown to readily penetrate the blood brain barrier allowing for convenient subcutaneous dosing. Thanks to their multimodal mechanism of action, Herantis’ molecules have the potential to stop the progression of Parkinson’s disease and significantly improve patients’ quality of life.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
Minoryx is developing leriglitazone, a brain penetrant and selective PPAR gamma agonist, for X-linked adrenoleukodystrophy (X-ALD) and other orphan CNS disorders. The company completed a phase 2/3 study in adult X-ALD patients with the chronic form (AMN) and has an ongoing study in pediatric patients with the acute form (cALD). Minoryx is planning to file a EU Marketing Authorization Application for X-ALD patients with AMN by mid 2022.
NervGen Pharma Corp., a clinical stage biotech company, dedicated to creating innovative treatments of nervous system injury due to trauma or disease of the nervous system.
NervGen’s platform technology is based around the broad inhibitory effects that chondroitin sulphate proteoglycans (CSPGs) have on repair in the CNS, whether the damage is due to acute disease or trauma, such as spinal cord injury or stroke, or due to chronic neurodegenerative diseases, such as multiple sclerosis or Alzheimer’s disease. The predominate receptor by which CSPGs mediate their effect is the receptor protein tyrosine phosphatase sigma (PTPσ). Modulation of the PTPσ receptor has been shown to promote several mechanisms of nerve repair, including axon regeneration, remyelination, increased plasticity, increased autophagy, and promotion of a non-inflammatory phenotype in the microglial cells. These pharmacodynamic effects have been accompanied by functional benefits crossing multiple neurological functions including motor function, sensory function, autonomic function, and cognitive functions. Benefits have been demonstrated in at least six different disease models including spinal cord injury, peripheral nerve injury, multiple sclerosis, optic neuritis, stroke, and cardiac ischemia.
NervGen initially plans to develop its lead product, NVG-291, for multiple sclerosis, Alzheimer's disease, and spinal cord injury.
NervGen is currently conducting a Phase 1 study in healthy volunteers. The company intends to initiate trials in patients in 2022.
NMD Pharma is a clinical-stage biotech company focused on developing life-changing therapies for neuromuscular diseases.
NMD Pharma develop small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels that have a promising therapeutic potential in a range of neuromuscular diseases in which muscle activation is failing leading to muscle weakness and excessive fatigue that compromise the ability of patients to conduct essential human behaviour and cause lack of independence. Initial focus is on myasthenia gravis, spinal muscular atrophy, Charcot-Marie Tooth’s disease, and sarcopenia. Each of these diseases has a profound impact on patient's functional level and their overall quality of life.
QurAlis is trailblazing the path to conquering amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets with next-generation precision medicines. QurAlis’ proprietary platforms and unique biomarkers enable the design and development of drugs that act directly on disease-causing genetic alterations. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a deep pipeline of antisense oligonucleotides and small molecule programs including addressing sub-forms of ALS that account for the majority of ALS patients.
Reviva is a clinical-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva’s pipeline currently includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and RP1208 in the United States (U.S.), Europe, and several other countries.
Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Our team works with patients and advocacy organizations to better understand their journey with mitochondrial disease and raise awareness of the unmet need our programs seek to address.
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogs to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders. The Company focuses on developing a product platform for therapeutic applications of bryostatin for several neurodegenerative, cognitive, and dysfunctions such as Alzheimer's, fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. Synaptogenix has targeted Bryostatin-1 due to its high potential and multi-modal efficacy: through protein kinase C (PKCϵ) activation, Bryostatin-1stimulates synaptic growth factors, amyloid-β degrading enzymes, as well as prevents Tau transformation into neurofibrillary tangles.
Unlearn is the only company creating Twintelligent RCTs™, which combine AI, Digital Twins, and novel statistical methods to enable smaller, more efficient trials. Twintelligent RCTs™ incorporate prognostic information from Digital Twins into randomized controlled trials to enable smaller control groups and generate evidence suitable for supporting regulatory decisions.
Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company primarily focused on the development of novel drugs that are designed to deter abuse in the treatment of central nervous system (CNS) disorders. The Company’s lead investigational product candidate, ADAIR is a proprietary abuse-deterrent formulation of immediate-release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy.
AlgoTherapeutix develops innovative solutions for complex pain.
AlgoTx's lead program is ATX01, a topical treatment for Chemotherapy-Induced Peripheral Neuropathy and other forms of peripheral neuropathic pain. ATX01 completed Phase I in late 2021 and is ready to enter a pivotal CIPN Phase II trial in Europe and the US.
AlgoTx raised 15 M€ in early funding including a Series A led by Bpifrance an Omnes Capital in 2020, and is currently raising a 20 M€ Series B to fund its Phase II development plan.
Allyx Therapeutics is a clinical stage company advancing disease modifying treatments for Alzheimer's disease. Our lead program, ALX-001, is an orally bioavailable drug which acts as a silent allosteric modulator of mGluR5 and has demonstrated a reversal of learning and memory deficits in multiple animal models of Alzheimer’s disease. Disease reversal was achieved by preserving and restoring damaged synapses.
Altoida, Inc is creating a new gold standard in brain health with Precision Neurology. Our innovative approach combines novel digital biomarkers (dBM) with immersive augmented reality (AR) and powerful artificial intelligence (AI). The result is our validated device and platform built on more than twenty years of cutting-edge scientific research. Our products are backed by peer-reviewed publications and multinational clinical trials, and are built by our expert team of scientists, clinicians and engineers. Altoida, Inc. is funded by M-Ventures, Eisai Innovation, Hikma Ventures, GreySky Venture Partners, FYRFLY, Alpana Ventures and VI Partners. For more on Altoida, please visit company's website or connect with us on LinkedIn and Twitter.
ASDERA develops and outlicenses IP for interventions to prevent or treat diseases with unmet needs and improve health in aging by using a patented computational biostatistics platform to identify complex genetic risk factors in small (n>500) genetic/epidemiological and phase 2/3 studies.
ASD-002 (US/EU pat. granted) is an oral drug (EU/US patents granted) to prevent children developing autism from becoming non-verbal (indep. valuated at >$1B, outlicensed until 2019, available again),
ASDERA developed IP for a family of first-in-class assets based on a different type of small molecules (intestinally absorbed, CoM pat. pend.), which target age-related conditions.
ASD-005 improving lysosomal function and autophagy by a novel mechanism of action. Applications include neurodegenerative diseases, incl. Alzheimer's, Parkinson's, and Huntington's disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and multiple sclerosis (MS), lysosomal storage diseases (Gaucher, NPC, TS, MPS, ...) ASD-006 (CoM pat pend.) improve cardiometabolic diseases increasing the risk of neurodegenerative diseases, incl. atherosclerosis (CVD), fibroses, NASH and diabetes (T2DM).
ASD-NP6 (CoM pat pend.) is based on the same MoA as ASD-005/006, but, as a dietary supplements, can be used as a preventive intervention to improve the natural process of aging and, thereby contributes to the prevention of neurodegenerative and cardiometabolic diseases.
These drug assets ASD-005/006 (some ready for phase 3, some optionally with accelerated approval under 505(b)(2) or as nano-devices), are expected to come to market as drugs within 2-5 years (ASD-005/006). The nutraceutical / functional food ASD-NP6 can come to market within 2-10 weeks.
Braintale is an innovative company dedicated to deciphering white matter to enable better care in neurology and intensive care with clinically validated prognostic solutions. Through sensitive and reliable measurements of brain white-matter microstructure alterations, Braintale offers a platform of digital biomarkers to assist decision-making in the clinic and enables identification of patients at risk, early diagnostics and monitoring of both disease progression and treatment efficacy. Building on more than 15 years in clinical development, Braintale’s products are developed to address medical need and fulfill expectations of healthcare professionals and patients alike.
Since its inception in 2018, the company has set up a complete quality management system and is now ISO :13485 :2016 certified, with a suite of products available on the European market.
Cenna Biosciences, Inc. is a clinical stage privately-held biopharmaceutical company in La Jolla CA, focused on the discovery and development of novel drugs for the prevention and treatment of Alzheimer’s disease (AD). The Company was founded in 2006 to translate over a decade’s academic research at UC San Diego by the Founders. There is a huge and growing market and patient population worldwide and there is no disease-modifying drug available. Cenna has a transformational, novel and different proprietary patented technology that arrests the underlying cause of the disease and that addresses previous failures by others. IND-enabling pre-clinical studies are completed and IND filing of Cenna’s first-in-class lead peptide drug candidate is planned within the next six months. Funding to date by Founders and $21M in NIH grants. The Company is seeking a $15 M investment to prepare an IND package and carry out Phase 1 clinical trials.
EpiVario is a preclinical stage biotechnology company focusing on developing treatments for neuropsychiatric disorders. Our co-founders, Dr. Shelley Berger and Dr. Philipp Mews, are leaders in the field of neuroepigenetics. They identified a key metabolic enzyme, acetyl CoA synthetase (ACSS2), that functions within the nucleus of hippocampal cells of the brain to activate genes critical for long term memory. This epigenetic mechanism plays a critical role in consolidating trauma-induced fear and stress responses and drug craving responses associated with addiction; thus, providing a new target for treating memory-related neuropsychiatric disorders, such as PTSD and drug and alcohol addiction.
Based on this paradigm-shifting finding, EpiVario is developing a small molecule drug to treat nicotine addiction. We demonstrated efficacy of an ACSS2 inhibitor in reducing drug seeking behavior in rats in a nicotine self-administration study with our collaborator Dr. Paul Kenny of Mount Sinai. We plan to show safety and efficacy in a phase 1b trial by the end of 2023.
Kinoxis Therapeutics Pty Ltd (Kinoxis) is a private, Australian-based, clinical stage company developing first-in-class therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric disorders. Kinoxis’ development candidates are novel, small molecules that were discovered through a comprehensive medicinal chemistry and screening program at the University of Sydney. Kinoxis is backed by Uniseed, Australia’s longest running venture fund, and a consortium of sophisticated investors, and secured funding from the US NIH National Institute on Drug Abuse for the development of its lead compound to mitigate opioid withdrawal symptoms.
Kinoxis’ lead candidate (KNX100) is being developed for the mitigation of opioid withdrawal symptoms. KNX100 has a novel, undisclosed mechanism of action and a Phase I clinical trial has commenced under a US IND. The company is also exploring other indications for its lead compound, KNX100, as promising preclinical results have been achieved in animal models of cocaine, methamphetamine, nicotine, and alcohol use disorders, as well as models of agitation and aggression.
Kinoxis’ second series of compounds target the oxytocin receptor, through either selective partial agonism or positive allosteric modulation. The brain oxytocin system has been identified as perhaps the most important molecular target for regulating social behaviour and is therefore a major target of interest for treating a wide range of mental disorders. The development of these compounds will be focused on treating conditions that feature social dysfunction as a core symptom, such as neurodevelopmental disorders (including autism spectrum disorder), social anxiety disorder, dementia (including Alzheimer’s disease), PTSD and schizophrenia. The KNX200 series of oxytocin receptor partial agonists are undergoing candidate selection stage using several pre-clinical animal disease models (Alzheimer’s, PTSD, ASD) and the KNX300/400 series of oxytocin receptor positive allosteric modulators are undergoing lead optimisation.
Lachesis is a clinical-stage biotech company dedicated to using our patented nasal spray technology to advance the treatment of diseases of the brain.
Our current focus is developing improved treatments for: - Dementia associated with Alzheimer's and Parkinson's disease - Organophosphorus poisoning - Agitation associated with Alzheimer's disease www.lachesisbiosciences.com/
NeuroDiagnostics, Inc. dba Synaps Dx
SYNAPS Dx was founded to commercialize the biomarker technology for the identification of Alzheimer’s Disease in people living with dementia. The DISCERN biomarker was developed through more than a decade of research by a team of scientists at the Blanchette Rockefeller Neuroscience Institute (BRNI). The SYNAPS Dx lab is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. The DISCERN test has received breakthrough designation from the FDA and has received coding and reimbursement from CMS for use in the Medicare population.
NeuroEM is a clinical-stage medical device company committed to developing and commercializing Transcranial Electromagnetic Wave Treatment (TEMT) as the first truly effective treatment and preventative against Alzheimer’s Disease (AD). With a strong foundation of pre-clinical studies in AD mice demonstrating safety, cognitive efficacy, and AD-targeted mechanisms, the Company recently published a clinical study demonstrating the ability of 2 months of in-home daily TEMT treatment to safely REVERSE memory impairment in AD patients. Moreover, beneficial changes in AD markers and brain imaging occurred in those AD patients. This study was extended to 2 1/2 years, during which time continued safety and stoppage of cognitive decline was observed in the multiple tasks evaluated. Untreated AD subjects would have markedly declined over that same period. No other AD therapeutic in clinical development can claim this level of safety and long-term cognitive benefit.
Based on these promising clinical results, the FDA awarded NeuroEM's MemorEM device in 2020 the first "Breakthrough" designation for any drug or device against AD. With a strong patent portfolio of three issued patents and 12 patent applications submitted, over $4M in grant support from NIH/NIA, and eight publications involving TEMT, NeuroEM is ideally positioned for success against AD. Having over a dozen collaborators/consultants to guide the Company’s management team, we at NeuroEM believe that our disruptive bioengineering technology will provide the first therapeutic intervention to stop and reverse the memory impairment of AD -- not just slow it down.
The investment opportunity can be summarized as follows: - Huge international market with unmet need - Clinical studies demonstrate safety & efficacy to stop and reverse AD cognitive decline by targeting the AD process - Disruptive technology supported by FDA’s “Breakthrough Designation” - Strong IP portfolio of patents/patent applications - A clear, low-cost pathway forward to FDA approval/commercialization within 3-4 years.
Origenis is a fully integrated privately owned German drug dis- covery Biotech company with a strong, proprietary technology platform and an innovative novel small molecule therapeutic drug pipeline.
Origenis has built a robust and cutting-edge drug discovery plat- form, that combines a strong artificial intelligence (AI) core engi- ne to guide, optimize and streamline all wet lab R&D activities. Cippix®, OnionTM, MolMind®, MOREsystem®, BRAINstormTM, EYEdealTM are Origenis core technologies to identify the right molecular targets for large market unmet medical needs and deliver a stream of novel and highly optimized small molecule drugs with effective patent protection.
Origenis focuses on highly challenging diseases for which no or insufficient treatment options are available. The deep optimiza- tion achieved with its technology platform delivers best-in-class drugs for molecular targets with first-in-class brain coverage. Origenis R&D focuses on diseases and conditions of Ageing: Fortification of the Blood Brain Barrier, Osteoporosis and Dia- betes, Vision and Hearing loss, Brain Inflammation, Anticancer-, and Antiviral treatments with excellent brain coverage. Origenis leverages synergies of molecular targets by maximizing the im- pact on several orthogonal disease targets.
PathMaker Neurosystems is a near-commercial stage neuromodulation company developing breakthrough non-invasive systems for the treatment of people with serious neurological disorders such as stroke and amyotrophic lateral sclerosis (ALS). With offices in Boston (U.S.) and Paris (France), PathMaker is collaborating with world-class institutions to rapidly bring to market disruptive products for treating brain and other neurological disorders with high unmet medical need. More than 48 million people in the U.S., Europe and Asia suffer profound disabilities due to stroke, ALS, spinal cord injury, multiple sclerosis, traumatic brain injury, cerebral palsy and other related neurological disorders. Our company's MyoRegulator® product is expected to be the world’s first non-invasive neuromodulation device to treat muscle spasticity, enabling treatment without the need for drugs or surgery. MyoRegulator® is based on PathMaker’s proprietary DoubleStim® technology for suppression of hyperexcitable spinal motor neurons. MyoRegulator® has been designated by the US Food and Drug Administration (FDA) as a “breakthrough medical device.” MyoRegulator® is an investigational medical device and is limited by Federal law to investigational use only. At PathMaker, we are opening up a new era of non-invasive therapy that promises to restore mobility and function in people with serious neurological disorders.
Sense Neuro Diagnostics is a medical technology company focused on improving outcomes for stroke and brain injury patients through technology innovations that enable faster detection and more effective triage.
Sense is developing non-invasive technology to enable continuous, real-time brain injury monitoring as well as rapid detection of traumatic brain injury and important stroke subtypes—ischemic stroke with large vessel occlusion, ischemic stroke without large vessel occlusion, and intracerebral hemorrhage.
Tessara Therapeutics Pty Ltd. is an Australian regenerative medicine company founded to develop synthetic human brain tissue platforms for several commercial uses, including implantable cell therapy and drug screening applications. Tessara aims to offer to the pharmaceutical industry a standardized preclinical assay system for drug target identification, validation and characterization of lead compounds addressing two major unmet needs in CNS drug development: translation from in vitro to in vivo and translation from animal to human physiology.